Cerevel Therapeutics Holdings, Inc.
CEREDelisted Aug 1, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805387
Cerevel Therapeutics Holdings, Inc. was delisted on Aug 1, 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.42B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 231
- Q2 2024, +23 vs. previous quarter
- 13F value
- $6.42B
- Reported value at the end of Q2 2024
- Superinvestors holding
- 1
- At the end of Q2 2024
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $0
- No comparable prior period
- Net income, FY2023
- -$432.8M
- No comparable prior period
- Free cash flow, FY2023
- -$346.1M
- No comparable prior period
- Revenue, Q1 FY2024
- –
- No comparable prior period
Superinvestors holding CERE, Q2 2024
Go to the superinvestors tab1 superinvestor reports holding Cerevel Therapeutics Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
2.0%
Cerevel Therapeutics Holdings, Inc.'s share of the portfolio
- Shares
- 2,151,641
- Value
- $88.0M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cerevel Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Coles N AnthonyDirector | SSale | −25.0K | $41.18 | −$1.03M | −49.1%25.9K after | 10b5-1 |
| Jun 5, 2024 (view filing) | Jun 3 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $40.61 | −$2.03M | −76.2%15.6K after | 10b5-1 |
| May 14, 2024 (view filing) | May 10 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $42.10 | −$2.10M | −76.2%15.6K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.33 | −$2.12M | −76.2%15.6K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $41.01 | −$2.05M | −76.2%15.6K after | 10b5-1 |
| Mar 4, 2024 (view filing) | Feb 29 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $41.16 | −$2.06M | −76.2%15.6K after | 10b5-1 |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Renger JohnChief Scientific Officer | SSale | −2.16K | $41.54 | −$89.8K | −25.3%6.37K after | |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Coles N AnthonyDirector | SSale | −2.51K | $41.54 | −$104.1K | −13.8%15.6K after | |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.24 | −$2.11M | −94.9%2.70K after | 10b5-1 |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Sanchez RamiroChief Medical Officer | SSale | −10.0K | $42.47 | −$424.7K | −40.5%14.7K after | 10b5-1 |
Top 10 13F holders, Q2 2024
See all 231 holdersThe largest institutional positions in Cerevel Therapeutics Holdings, Inc. at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 65,679,781 | $2.69B | 57.02% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 10,794,876 | $441.4M | 10.65% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 7,539,547 | $308.3M | 4.11% | −16,008−0.2% | Reduced |
| Vanguard Group Inc | 7,154,343 | $292.5M | 0.01% | −309,568−4.1% | Reduced |
| BlackRock Inc. | 3,560,931 | $145.6M | 0.00% | −1,887,689−34.6% | Reduced |
| FIL Ltd | 3,252,000 | $133.0M | 0.13% | +3,000+0.1% | Added |
| State Street Corp | 3,109,886 | $127.2M | 0.01% | −418,584−11.9% | Reduced |
| Alpine Associates Management Inc. | 2,353,694 | $96.2M | 4.63% | +12,300+0.5% | Added |
| Norges Bank | 2,335,746 | $95.5M | 0.01% | +1,610,692+222.1% | Added |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95.3M | 3.65% | 00.0% | Unchanged |